Document is current

Article History

Received: 22 December 2023

Accepted: 16 March 2025

First Online: 8 April 2025

Change Date: 5 July 2025

Change Type: Update

Change Details: This article has been updated to amend the license information.

Declarations

:

: Ethic approval for the current study was attained from the Research Ethics Board at Centre for Addiction and Mental Health (#030-2022). Written informed consents were provided by all participant prior to the individual interviews. The study was conducted in compliance with all relevant guidelines and regulations.

: N/A.

: SLR holds a Senior National Health and Medical Research Council (NHMRC) Fellowship (GNT1154651) in Australia. SK reports grants from the Labatt Family Innovation Fund in Brain Health (Department of Psychiatry, University of Toronto), the Max Bell Foundation, the Canadian Centre on Substance Use and Addiction, the Ontario Ministry of Health and Long-Term Care (MOHLTC), the Canadian Institutes of Health Research (CIHR). SK has received honorarium for past consultation from EmpowerPharm. DC has received grant monies for research from Servier, Boehringer Ingelheim; Travel Support and Honoraria for Talks and Consultancy from Servier, Seqirus, Lundbeck. DC is a founder of the Optimal Health Program (OHP), and holds 50% of the IP for OHP; and is part owner of Clarity Healthcare. DC does not knowingly have stocks or shares in any pharmaceutical company. LDH reports grants from CIHR, the University of Toronto, and the Centre for Addiction and Mental Health. The remaining authors declare that they have no declarations or competing interests.